Sight Sciences Releases Preliminary Q4 and 2025 Financial Results

Published on January 15, 2026
MENLO PARK, Calif.—Sight Sciences, Inc., (Nasdaq: SGHT), an eyecare technology company, has reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2025. Fourth quarter 2025 total revenue is expected to be in the range of $20.3 million to $20.4 million, the company advised, an increase of 7 percent at the estimated midpoint compared with the prior-year period. Full year 2025 total revenue is expected to be in the range of $77.3 million to $77.4 million, a decrease of 3 percent at the estimated midpoint compared with the prior year, the company reported.
Continue reading on website
Other news

Patients’ Cardiovascular Risk Score May Predict Development of Multiple Eye Diseases, New Study Shows

January 15, 2026
LOS ANGELES—A cardiovascular risk score, already routinely used in primary care, may predict who will develop serious eye diseases, according to a UCLA Health study published earlier this month. UCLA Health said researchers involved in the study found that people with higher cardiovascular risk scores were “significantly more likely to develop conditions including age-related macular degeneration,

Glaukos Reports Preliminary Q4 and 2025 Results, Reaffirms 2026 Revenue Guidance

January 15, 2026
ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, has announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance. The company advised that tot